Literature DB >> 3391264

Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase.

Q S Yu1, J R Atack, S I Rapoport, A Brossi.   

Abstract

Reaction of (-)-eseroline (1) with alkyl, aryl and aralkylisocyanates afforded a series of carbamate analogues of (-)-physostigmine (2) which were assayed for inhibition of acetyl- and butyrylcholinesterase (AChE and BChE, respectively) in vitro. Included in this study were two N-alkyl-substituted carbamates 9 and 14 obtained from (-)-eseroline (1) with dialkylcarbamoyl chlorides, and allophanates 12 and 13 obtained as by-products in the reaction of 1 and benzylcarbamoyl eseroline (8) with benzyl isocyanate. Whereas none of the analogues studied was more potent than 2 against electric eel AChE, and carbamates 6, 7 and 8 were all more than 3 times more potent against human plasma BChE than 2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391264     DOI: 10.1016/0014-5793(88)81317-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  High-affinity carbamate analogues of morphinan at opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

2.  Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.

Authors:  C Blandizzi; B De Paolis ; R Colucci; G Lazzeri; F Baschiera; M Del Tacca
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

Authors:  B P Imbimbo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.

Authors:  S Iijima; N H Greig; P Garofalo; E L Spangler; B Heller; A Brossi; D K Ingram
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.